Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (4197)	6/26/2001 9:35:57 AM
From: Biomaven	Read Replies (1) of 52153

Jim, <<INHL>> No efficacy issues that I saw here. On most measures you wouldn't expect statistically significant improvement over injectable insulin. But in fact they did show such improvement on one measure (% reaching HbA1c 7% target), and the lack of weight gain is also very nice. The two concerns are the antibodies and the fibrosis. Nobody really seems to know if the antibody issue is of any long-term significance. The fibrosis issue is still crucial - the issue now seems to be whether the single case was a pre-existing condition that they missed in the screening. The FDA will likely be cautious here. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next